PDS Biotechnology Corp Finance Lease, Right-of-Use Asset, Amortization
PDS Biotechnology Corp (PDSB) reported Finance Lease, Right-of-Use Asset, Amortization of $16.41 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-13
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $6.74K, a 30.28% decline year-over-year.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $9.67K, a 0.00% change year-over-year.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $9.67K, a 0.03% increase year-over-year.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $9.67K, a 0.01% decline year-over-year.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for fiscal 2025 was $38.68K, a 0.01% increase from fiscal 2024.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for fiscal 2024 was $38.68K, a 3.22% decline from fiscal 2023.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for fiscal 2023 was $39.97K, a 18.42% decline from fiscal 2022.
- PDS Biotechnology Corp finance lease, right-of-use asset, amortization for fiscal 2022 was $48.99K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $16.41K 10-Q · filed 2026-08-13 | $26.08K derived: sum of 3 quarters · filed 2026-08-13 | $35.75K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.67K 10-Q · filed 2026-05-14 | $19.34K derived: sum of 2 quarters · filed 2026-05-14 | $29.01K derived: sum of 3 quarters · filed 2026-05-14 | $38.68K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $9.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $19.34K derived: sum of 2 quarters · filed 2026-03-30 | $29.01K derived: sum of 3 quarters · filed 2026-08-13 | $38.68K 10-K · filed 2026-03-30 |
| 2025-09-30 | $9.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $19.34K derived: sum of 2 quarters · filed 2026-08-13 | $29.01K 10-Q · filed 2025-11-13 | $38.68K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $9.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $19.34K 10-Q · filed 2026-08-13 | $29.01K derived: sum of 3 quarters · filed 2026-08-13 | $38.68K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.67K 10-Q · filed 2026-05-14 | $19.34K derived: sum of 2 quarters · filed 2026-05-14 | $29.01K derived: sum of 3 quarters · filed 2026-05-14 | $38.68K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $19.34K derived: sum of 2 quarters · filed 2026-03-30 | $29.01K derived: sum of 3 quarters · filed 2026-03-30 | $38.68K 10-K · filed 2026-03-30 |
| 2024-09-30 | $9.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $19.34K derived: sum of 2 quarters · filed 2025-11-13 | $29.01K 10-Q · filed 2025-11-13 | $38.68K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $19.34K 10-Q · filed 2025-08-13 | $29.01K derived: sum of 3 quarters · filed 2025-08-13 | $38.68K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $9.67K 10-Q · filed 2025-05-14 | $19.34K derived: sum of 2 quarters · filed 2025-05-14 | $29.01K derived: sum of 3 quarters · filed 2025-05-14 | $38.68K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $9.67K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $19.34K derived: sum of 2 quarters · filed 2025-03-27 | $29.01K derived: sum of 3 quarters · filed 2025-03-27 | $39.97K 10-K · filed 2025-03-27 |
| 2023-09-30 | $9.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $19.34K derived: sum of 2 quarters · filed 2024-11-14 | $30.30K 10-Q · filed 2024-11-14 | $41.87K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $9.67K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $20.63K 10-Q · filed 2024-08-13 | $32.20K derived: sum of 3 quarters · filed 2024-08-13 | $69.62K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $10.96K 10-Q · filed 2024-05-15 | $22.53K derived: sum of 2 quarters · filed 2024-05-15 | $59.95K derived: sum of 3 quarters · filed 2024-05-15 | $59.95K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $11.57K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $48.99K derived: sum of 2 quarters · filed 2024-03-28 | $48.99K derived: sum of 3 quarters · filed 2024-03-28 | $48.99K 10-K · filed 2024-03-28 |
| 2022-09-30 | $37.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $37.42K derived: sum of 2 quarters · filed 2023-11-14 | $37.42K 10-Q · filed 2023-11-14 | $37.42K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 10-K · filed 2023-03-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |